William R. Osgood, Ph.D. | Chief Executive Officer
Dr. Osgood joined ThermoGenesis Corp. in January 2006 as General Manager of Operations, and currently serves as Chief Executive Officer. He brings more than 20 years of leadership experience in the operations of Class II and III medical device companies to the Company, and most recently served as Senior Vice President of Sorin Group Company's $250 million cardiopulmonary business, where he managed worldwide commercial operations and research and development for its intra-operative heart and lung devices and related disposables. Dr. Osgood joined Sorin after the company acquired COBE Cardiovascular Inc., where he led the industrial integration of plants worldwide. Prior to this, he was Vice President of Baxter Healthcare's $800 million CardioVascular Group, where he successfully reengineered business processes across multiple divisions resulting in sales growth, cost reductions and deeper customer partnerships. He holds a Ph.D. in Systems Engineering, a Masters Degree of Business Administration, a Masters Degree of Science in Control Theory and a Bachelor of Science Degree in Engineering from University of California, Los Angeles.

Philip H. Coelho | Chief Technology Architect
Mr. Coelho was named President of ThermoGenesis Corp. in September 1989, and currently serves as Chief Technology Architect. From October 1986 to September 1989, Mr. Coelho held the position of Vice President and Director of Research, Development and Manufacturing. From October 1989 to July 2007 Mr. Coelho served as Chief Executive Officer. Prior to his association with ThermoGenesis, Mr. Coelho was President of Castleton, Inc. (October 1983 to October 1986), a company that developed and licensed the ultra-rapid heat transfer technology to ThermoGenesis Corp. Mr. Coelho holds a Bachelor of Science degree in Mechanical Engineering from the University of California, Davis, and is the inventor or co-inventor on the majority of the company's patents.

Matt T. Plavan | Chief Financial Officer
Mr. Plavan Joined ThermoGenesis in May of 2005 as Chief Financial Officer. Mr. Plavan brings 20 years of financial leadership, P&L responsibility and general management experience to the Company. Before joining the Company, Mr. Plavan served from 2002 to 2005 as Chief Financial Officer of StrionAir, Inc., an air purification product development and marketing company. Prior to that, Mr. Plavan was the Chief Financial Officer for a wireless device management Company, Reason Inc., from 2000 to 2002. During the preceding seven years, 1993 through 2000, Mr. Plavan served in a number of key financial and operating leadership roles within McKesson and McKesson-acquired companies, including most recently, Vice President of Finance for a $300 million ehealth division. Prior to that, Mr. Plavan was an audit manager in the Audit and Risk Advisory Services group of Ernst & Young LLP. Mr. Plavan earned his Bachelors Degree in Business Economics from The University of California at Santa Barbara, California. Mr. Plavan became a Certified Public Accountant in 1992.


John Chapman, Ph.D | Vice President of R&D and Scientific Affairs
Dr. Chapman serves as ThermoGenesis Corp's Vice President of Scientific Affairs and is responsible for directing the company's scientific strategy and life science initiatives in cell therapy and wound care. John Chapman, Ph.D is a seasoned leader of medical product Research and Development programs with 20 years of experience in integrating life sciences, chemistry and biomedical engineering to develop new products. Prior to joining ThermoGenesis Corp., Dr. Chapman was the Vice President of Research and Development at V.I. Technologies from 1999 to 2005. From 1983 to 1999, Dr. Chapman was with Baxter Healthcare Corporation in various scientific positions of product development with his last position being Scientific Director in the Fenwal Division. He holds a Ph.D. in Toxicology and has authored 22 issued U.S. patents and 32 scientific publications in the fields of chemistry, devices, biologics and blood processing.

Hubert E. Huckel, M.D. | Chairman
Director, Titan Pharmaceuticals, Inc.
Dr. Huckel joined the Board of Directors in 1997. He is a founder of Catalyst Pharmaceutical Partners and serves as its Chairman of the Board. In addition, he sits on the Board of Directors of Titan Pharmaceuticals, Inc., Amarin Pharmaceuticals, plc and Valera Pharmaceuticals, Inc. He was affiliated with the Hoechst Group (now Aventis) for nearly thirty years and, at the time of his retirement, was Executive Chairman of the Board of Hoechst-Roussel Pharmaceuticals, Inc. Dr. Huckel received his M.D. degree from the University of Vienna, Austria, and is a member of the Rockefeller University Council.


Philip H. Coelho | Director


William R. Osgood, Ph.D. | Director


Patrick J. McEnany | Director
Patrick J. McEnany is a founder and Chief Executive Officer of Catalyst Pharmaceutical Partners, a drug development company formed in January 2002. From 1991 to April of 1997, Mr. McEnany was Chairman and President of Royce Laboratories, Inc., a Miami, Florida- based manufacturer of generic prescription drugs. Following the merger of Royce into Watson Pharmaceuticals, Inc., Mr. McEnany served (1997-1998) as President of the wholly-owned Royce Laboratories subsidiary and Vice President of Corporate Development for Watson Pharmaceuticals, Inc. He was Vice Chairman and Director of the National Association of Pharmaceutical Manufacturers (1993-1997) and currently serves on the Board of Directors for Renal CarePartners, Inc., an operator of kidney dialysis centers, and the Jackson Memorial Hospital Foundation. Mr. McEnany sat on the Board of Directors of Med/Waste, Inc. His tenure was March 2000 to February 13, 2002, when the company filed for voluntary bankruptcy protection under federal bankruptcy laws.


Woodrow Myers, M.D. | Director
Woodrow Myers, M.D., M.B.A. has served director of ThermoGenesis since June 2006. Dr. Myers, a director at Stanford University Hospital and visiting adjunct professor of medicine at the UCLA School of Medicine, is the former executive vice president and chief medical officer of WellPoint, Inc., where he established the Health Quality Assurance Division. Prior to his position at WellPoint, Dr. Myers served as the director of health care management at the Ford Motor Company where he initiated quality assurance metrics for Ford healthcare vendors and established new global health and safety policies to benefit Ford and its employees. He is a former health commissioner for the city of New York and the state of Indiana, past chairman of the Visiting Committee for the Harvard School of Public Health and has served as a member of the Harvard University Board of Overseers and the Stanford University Board of Trustees. Dr. Myers holds medical and business degrees from Harvard and Stanford, respectively.

Mahendra S. Rao, M.D., Ph.D. | Director
Mahendra S. Rao is a Vice President, Stem Cells and Regenerative Medicine for Invitrogen Corporation, a corporation that provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition since 2006.  From 2001 to 2005 he was Section Chief (stem cell)/Senior Investigator at the National Institute of Aging’s Laboratory of Neuroscience.  He currently services as an Associate Professor at the NCBS Bangalore India and Neurosciences-John Hopkins University School of Medicine.  He holds an M.D. in Medicine and a Ph.D. in Dev. Neurobiology from the Bombay University.  He has authored over twenty submitted, five issued patents and 250 scientific publications in the field of stem cell therapies and has chaired the US FDA cell and gene therapy advisory committee.